eagle-i The Ohio State UniversityThe Ohio State University

Investigational new Drug or Device Exemption Support

eagle-i ID


Resource Type

  1. Service


  1. Resource Description
    Clinical Trials for drugs being developed for initial use in humans as well as for FDA approved drugs but being investigated for additional use(s) require an Investigational New Drug Approval (IND) from the FDA prior to commencing, and which is required for IRB submission and approval for Ohio State and for Nationwide Children’s Hospital . For clinical trials involving marketed drug(s) for alternative use an IND Exemption may be an acceptable alternative. The CCTS, in collaboration with the OSU Drug Development Institute and Nationwide Children’s Hospital’s Drug and Device Development Services, can help research teams navigate these potentially complex processes.
  2. Contact
  3. Service Provided by
    CCTS Regulatory Knowledge and Support
  4. Website(s)
Provenance Metadata About This Resource Record

    Copyright © 2016 by the President and Fellows of Harvard College
    The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016